Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

NCT04770272 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

442

Enrollment

INDUSTRY

Sponsor class

Stopped The trial stopped recruitment prematurely after a first planned interim analysis of the first 100 pCR results (given that a probability of less than 2.5% of meeting the primary endpoint was estimated).

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: Atezolizumab 840 MG in 14 ML Injection
DRUG: Atezolizumab 1200 MG in 20 ML Injection
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Epirubicin
DRUG: Cyclophosphamide
PROCEDURE: Biopsy Arm A
PROCEDURE: Biopsy Arm B
PROCEDURE: Surgery

Sponsor

Palleos Healthcare GmbH

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]